C1 Inhibitor Registry in the Treatment of Hereditary Angioedema (HAE) Attacks

Pharming Healthcare

Status: Completed

Conditions: Hereditary Angioedema

Treatments: Drug: rhC1INH or pdC1INH

Study type: Observational

Funder types: Industry

Identifiers

NCT01397864

C1 1412

Details and patient eligibility

About

This is a non-interventional treatment Registry of Hereditary Angioedema (HAE) patients treated with C1 inhibitor, either plasma-derived (pdC1INH) or the recombinant human form (rhC1INH / Ruconest), to observe adverse events and insufficient efficacy, and to assess the immunological profile following single and repeated treatment with Ruconest.

Full description

see below

Enrollment: 181 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Decision to treat the HAE patient with C1 inhibitor (either Ruconest or pdC1INH)
• Patients must give written informed consent

Exclusion criteria

• A diagnosis of acquired C1INH deficiency (AAE)

Trial design

181 participants in 1 patient group

Hereditary Angioedema

Treatment:

Drug: rhC1INH or pdC1INH